JSPR vs KALA

Jasper Therapeutics, Inc. vs KALA BIO, Inc. — Valuation Comparison 2026

JSPR

Biotechnology
Jasper Therapeutics, Inc.
Quality
3.5
out of 10
Value Trap
36
LOW
Price
$0.89
Last close
Models
7/13
Active
VS

KALA

Biotechnology
KALA BIO, Inc.
Quality
3.4
out of 10
Value Trap
24
SAFE
Price
$2.29
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType JSPR Fair ValueJSPR Upside KALA Fair ValueKALA Upside
Bayesian DCF Intrinsic $0.49 -44.6% $0.06 -97.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.03 -96.7% $0.36 -84.1%
Dynamic NAV Asset-Based $2.18 +144.9% $4.24 +85.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for JSPR vs KALA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JSPR vs KALA — Which Stock Is More Undervalued?

JSPR scores higher with a 3.5/10 quality rating vs KALA's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jasper Therapeutics, Inc. (JSPR) and KALA BIO, Inc. (KALA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JSPR currently trades at $0.89 with a QOC of 3.5/10, while KALA trades at $2.29 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).